At a glance
- Company
- Co-Diagnostics, Inc.
- Ticker
- NASDAQ: CODX
- Announcement
- Expansion
- Location
- South Asia
Key figures
- Estimated addressable market
- $13.0 billion
Products and programs
Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka, significantly increasing its addressable market to an estimated $13.0 billion. The expansion supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions.
To view the full press release, visit https://ibn.fm/2aATV
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
For more information, https://co-dx.com/
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
Which countries are included in CoSara’s expanded South Asia territory?
The agreement adds Bangladesh, Pakistan, Nepal and Sri Lanka to CoSara Diagnostics Pvt. Ltd.’s commercial and distribution territory. CoSara is the Indian joint venture named in the announcement. The expansion is intended to support regional distribution as the company develops channels for its molecular diagnostics solutions.
Which products does CoSara plan to commercialize in the expanded territory?
The announcement identifies the CoSara PCR Pro point-of-care platform and the SARAGENE product line as planned for commercialization in the expanded territory. That activity is subject to regulatory approvals. The release describes the broader effort as building regional distribution channels and preparing for wider deployment of molecular diagnostics solutions.
What does the announced $13.0 billion addressable market estimate refer to?
The announcement says the territorial expansion significantly increases the company’s addressable market to an estimated $13.0 billion. It does not provide a breakdown of that estimate by country, product or customer segment. The figure is presented as an estimate associated with the broader territory, rather than as sales or revenue already achieved.
How does a distribution agreement generally help a diagnostics company enter a new market?
A distribution agreement typically gives a distributor the right to market, sell or deliver a supplier’s products within an agreed territory. The parties may set conditions for regulatory clearances, product handling and sales responsibilities. Such an agreement can establish a route to market, but it does not itself guarantee product approval, availability or sales.
